Public Sector Pension Investment Board Grows Holdings in BioLife Solutions, Inc. $BLFS

Key Points

• The Public Sector Pension Investment Board increased its stake in BioLife Solutions, Inc. by 27.2% in Q1, now owning approximately 0.24% of the company valued at $2.62 million.
• Several analysts have provided positive ratings for BioLife Solutions, with a consensus rating of "Buy" and a target price of $31.29.
• BioLife Solutions reported a loss per share of ($0.33) in its last earnings, missing the consensus estimate, despite achieving revenue of $25.42 million.

Public Sector Pension Investment Board boosted its position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 27.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 114,696 shares of the medical equipment provider's stock after acquiring an additional 24,548 shares during the quarter. Public Sector Pension Investment Board owned 0.24% of BioLife Solutions worth $2,620,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Invesco Ltd. lifted its holdings in BioLife Solutions by 9.6% in the first quarter. Invesco Ltd. now owns 3,551,054 shares of the medical equipment provider's stock worth $81,106,000 after buying an additional 311,585 shares during the period. Fred Alger Management LLC raised its holdings in BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider's stock worth $41,386,000 after acquiring an additional 16,274 shares during the last quarter. Millennium Management LLC raised its holdings in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock worth $29,733,000 after acquiring an additional 377,111 shares during the last quarter. Palisade Capital Management LP raised its holdings in BioLife Solutions by 13.7% in the 1st quarter. Palisade Capital Management LP now owns 947,085 shares of the medical equipment provider's stock worth $21,631,000 after acquiring an additional 113,937 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in BioLife Solutions by 4.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider's stock worth $23,028,000 after acquiring an additional 40,416 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

Insider Transactions at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the business's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total transaction of $23,800,000.00. Following the completion of the transaction, the insider directly owned 7,707,165 shares in the company, valued at $183,430,527. The trade was a 11.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 2,008,831 shares of company stock worth $47,499,658 in the last three months. Insiders own 2.20% of the company's stock.

BioLife Solutions Stock Performance

NASDAQ:BLFS traded down $0.26 during midday trading on Monday, reaching $25.65. 464,871 shares of the stock traded hands, compared to its average volume of 573,846. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.55. The business has a 50-day moving average of $22.39 and a two-hundred day moving average of $23.37. The stock has a market capitalization of $1.23 billion, a PE ratio of -213.73 and a beta of 1.76.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.31). The company had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%. BioLife Solutions has set its FY 2025 guidance at EPS. Research analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BLFS shares. Stephens started coverage on shares of BioLife Solutions in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price objective for the company. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Zacks Research upgraded shares of BioLife Solutions to a "strong-buy" rating in a research note on Monday, August 11th. Finally, HC Wainwright restated a "buy" rating and set a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. Based on data from MarketBeat, BioLife Solutions has an average rating of "Buy" and a consensus target price of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.